3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Completed
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
3
Gastrointestinal
2
Plasma cell
1
Genitourinary
1
Conditions
Rectal Neoplasms
2
Neoplasms by Site
1
Neoplasms
1
Colonic Neoplasms
1
Carcinoma
1
Interventions
Oxaliplatin
780
Fluorouracil
638
Capecitabine
575
Gemcitabine
478
Leucovorin
459
Bevacizumab
445
Irinotecan
444
Cisplatin
338
Radiotherapy
283
Cetuximab
252
Paclitaxel
180
S 1 (combination)
176
pembrolizumab
173
Docetaxel
156
Drug Therapy
147
Nivolumab
146
sintilimab
143
tislelizumab
131
apatinib
131
130-nm albumin-bound paclitaxel
128
Folfox protocol
121
durvalumab
119
Albumin-Bound Paclitaxel
117
camrelizumab
107
lenvatinib
106
Panitumumab
106
regorafenib
102
Surgical Procedures, Operative
102
Sorafenib
99
Radiation
88
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2
×
L-BLP25
×
Gastrointestinal
×
Clear all
NCT01462513
2018-02-13
LICC
Johannes Gutenberg University Mainz
Phase 2
Completed
122 enrolled
NCT01507103
2017-01-13
SPRINT
Merck KGaA, Darmstadt, Germany
Phase 2
Completed
124 enrolled
9 charts